Figure 4 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei

BRAF inhibitor suppresses subcutaneous tumor growth in a BRAFV600E PMP-PDX model. BRAFV600E mutant PMP-PDX cells from PMP5.1 were subcutaneously implanted in mice and treated with vehicle, intraperitoneal cetuximab (20 mg/kg), oral encorafenib (20 mg/kg), or doublet (n = 10–12/group). A, Tumor growth curve of the treated mice overtime. Mean ± SEM is shown. B, Graphs show the Western blot quantification of pEGFR/EGFR (left) and pERK/ERK (right) ratio from samples of representative excised tumors at day 4 after treatment. Mean ± SD is shown. C, Representation of the fold change (FC) in tumor volume for each tumor at day 44 after treatment. Mean ± SEM is shown. Significant differences were assessed using one-way ANOVA and Dunnett’s multiple comparisons tests compared to vehicle group (*, P value < 0.05; ****, P value < 0.0001; A and C). D, Image of representative tumors from each group at the end of the experiment. E, Survival curves represent PFS percentage of each tumor. Mice survival was evaluated by the Kaplan–Meier survival curve and log-rank test group (****, P value < 0.0001). F, Ki-67 IHC was performed from all tumor samples at the end of the experiment. Images from a representative tumor from vehicle, cetuximab, encorafenib and doublet groups. Scale bar, 100 μm. PMP, Pseudomyxoma peritonei; PDX, Patient-derived xenografts.